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Abstract
IMPORTANCE—In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are 
reported by investigators rather than by patients. There is increasing interest to collect 
symptomatic AE data via patient-reported outcome (PRO) questionnaires, but it is unclear whether 
it is feasible to implement this approach in multicenter trials.
OBJECTIVE—To examine whether patients are willing and able to report their symptomatic AEs 
in multicenter trials.
DESIGN, SETTING, AND PARTICIPANTS—A total of 361 consecutive patients enrolled in 
any 1 of 9 US multicenter cancer treatment trials were invited to self-report 13 common 
symptomatic AEs using a PRO adaptation of the National Cancer Institute’s Common 
Basch et al. Page 3













Terminology Criteria for Adverse Events (CTCAE) via tablet computers at 5 successive clinic 
visits. Patient adherence was tracked with reasons for missed self-reports. Agreement with 
clinician AE reports was analyzed with weighted κ statistics. Patient and investigator perspectives 
were elicited by survey. The study was conducted from March 15, 2007, to August 11, 2011. Data 
analysis was performed from August 9, 2013, to March 21, 2014.
RESULTS—Of the 361 patients invited to participate, 285 individuals enrolled, with a median 
age of 57 years (range, 24–88), 202 (74.3%) female, 241 (85.5%) white, 73 (26.8%) with a high 
school education or less, and 176 (64.7%) who reported regular internet use (denominators varied 
owing to missing data). Across all patients and trials, there were 1280 visits during which patients 
had an opportunity to self-report (ie, patients were alive and enrolled in a treatment trial at the time 
of the visit). Self-reports were completed at 1202 visits (93.9% overall adherence). Adherence was 
highest at baseline and declined over time (visit 1, 100%; visit 2, 96%; visit 3, 95%; visit 4, 91%; 
and visit 5, 85%). Reasons for missing PROs included institutional errors in 27 of 48 (56.3%) of 
the cases (eg, staff forgetting to bring computers to patients at visits), patients feeling “too ill” in 8 
(16.7%), patient refusal in 8 (16.7%), and internet connectivity problems in 5 (10.4%). Patient-
investigator CTCAE agreement was moderate or worse for most symptoms (most κ < 0.05), with 
investigators reporting fewer AEs than patients across symptoms. Most patients believed that the 
system was easy to use (234 [93.2%]) and useful (230 [93.1%]), and investigators thought that the 
patient-reported AEs were useful (133 [94.3%]) and accurate (119 [83.2%]).
CONCLUSIONS AND RELEVANCE—Participants in multicenter cancer trials are willing and 
able to report their own symptomatic AEs at most clinic visits and report more AEs than 
investigators. This approach may improve the precision of AE reporting in cancer trials.
In cancer trials, it is standard practice for clinical investigators to report adverse events 
(AEs) using the US National Cancer Institute’s (NCI’s) Common Terminology Criteria for 
Adverse Events (CTCAE).1 The CTCAE is a library of items representing approximately 
800 discrete AEs graded using a 5-point numerical grading system, with each grade 
anchored to discrete clinical criteria. Approximately 10% of CTCAE items represent 
symptoms (eg, nausea and sensory neuropathy) that, like nonsymptom AEs (eg, neutropenia 
and retinal detachment), have historically been reported by investigators and not by 
patients.2 However, there is empirical evidence that investigators miss up to half of 
symptomatic AEs, that clinician interrater reliability for reporting symptomatic AEs is 
generally low, and that collection of this information directly from study participants as 
patient-reported outcomes (PROs) may improve the reliability and precision of symptomatic 
AE detection.3–7
Patient-reported outcomes are the standard used in clinical trials for measurement of health-
related quality of life, physical functioning, and disease-related symptoms and are of 
growing interest in hospital quality assessment and comparative effectiveness research.8–14 
In 2005, the Food and Drug Administration published a draft guidance document (finalized 
in 2009) recommending the use of PROs whenever measuring concepts in clinical trials that 
are best evaluated from the patient’s perspective,15 with a similar statement from the 
European Medicines Agency.16
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Although PROs are increasingly used in these other contexts, they are not yet standard for 
AE reporting in clinical trials. The need for such an approach is particularly salient in 
oncology given that cancer therapies often carry substantial toxicity burdens that contribute 
to treatment nonadherence, discontinuation, dose reduction, and discomfort.17–20 In a survey 
of more than 700 cancer clinical investigators and research staff, more than 90% believed 
that patient reporting of symptomatic AEs could improve data completeness, accuracy, 
meaningfulness, and actionability compared with the current standard approach based on 
physician reporting.21 Single-center studies have demonstrated that collecting symptomatic 
AE information via the internet from patients receiving chemotherapy is feasible.22,23
Therefore, the NCI supported a national cooperative group study to assess the feasibility of 
asking patients to report their symptomatic AEs using plain language items based on 
CTCAE, version 3.0,22,23 via a web-based platform24 during participation in national 
multicenter NCI-sponsored cancer trials.
Methods
Patients and Sites
Patients enrolled in any 1 of 9 US national multicenter cancer trials supported by the NCI 
were eligible for simultaneous participation in this Cancer and Leukemia Group B 
(CALGB) correlative PRO feasibility study (CALGB 70501; clinicaltrials.gov, 
NCT00417040). The CALGB study is now part of the Alliance for Clinical Trials in 
Oncology. Patients could be registered to the PRO feasibility study at any time up until and 
including the second scheduled visit (cycle 2 of therapy). Included were 4 breast cancer 
trials,25–281 colorectal cancer trial,29 2 lung cancer trials,30,311 prostate cancer trial,32 and 1 
supportive care trial.33 (eTable 1 in the Supplement provides details of each trial.) This PRO 
feasibility study was approved by the institutional review board at each accruing site 
(eAppendix in the Supplement), and all participants provided written informed consent that 
was separate from their consent to enroll in the associated treatment trial.
At each site, clinical research professionals (CRPs) underwent a standardized 20-minute, 
web-enabled teleconference before initiation of enrollment to learn how to use a secure 
online questionnaire system that has been usability tested and employed in multiple previous 
studies.22–24 The CRPs were taught how to register patients into the system and administer 
symptom questionnaires to patients via wireless tablet computers. Sites were assessed for 
wireless internet connectivity in clinic waiting areas and the availability of computers, and 
wireless tablet computers and/or wireless connection hardware were provided to sites when 
needed.
Consecutive patients enrolled in the treatment trials were approached and invited to 
participate in the feasibility study if they were able to read and comprehend English and able 
to see a computer screen or were accompanied by a companion who could read a screen to 
the patient. Reasons for refusal to participate were systematically tracked. At the time of 
enrollment, site CRPs educated each participant to complete self-reported questions via 
tablet computers using a 10-minute standardized training session.
Basch et al. Page 5














The AE patient questionnaire included plain language items based on CTCAE, version 3.0 
(eTables 2 and 3 in the Supplement). These items served as a basis for the NCI’s recently 
developed PRO-CTCAE item library.34,35 Specifically, patients completed questions about 
13 symptomatic AEs, including anorexia (appetite loss), constipation, cough, diarrhea, 
dyspnea (shortness of breath), fatigue, hand or foot reaction or rash, mucositis (mouth 
sores), nausea, neuropathy, pain, vomiting, and watery eyes (eTable 2 in the Supplement). 
These questions were graded similarly to the clinician CTCAE using a 5-point ordinal scale 
for responses, with verbal descriptors of clinical anchors except with the use of lay 
terminology. For example, grade 3 anorexia is defined for clinicians in the CTCAE as 
“associated with significant weight loss or malnutrition (eg, inadequate oral caloric and/or 
fluid intake); IV [intravenous] fluids, tube feedings, or TPN [total parenteral nutrition] 
indicated” and grade 3 wording for the PRO adaptation is, “I am losing a lot of weight or I 
am malnourished, and I am taking in very little food or fluids (or I have needed to get IV 
fluids, tube feedings, or IV nutrition).”22(p3555) To harmonize with the general approach to 
clinician CTCAE reporting, patient questionnaire instructions specified the following recall 
period: “Please answer the following questions to tell us the worst your symptoms have been 
since your last chemotherapy treatment. If you have not received chemotherapy, or your 
treatment has been held, please tell us the worst your symptoms have been since your last 
chemotherapy visit.”22(p3555) In the 9 clinical trials, treatment cycle length varied, and the 
recall periods for patient questionnaires therefore varied based on cycle length. Specifically, 
the cycle length was weekly in 1 trial, every 2 weeks in 1 trial, every 3 weeks in 5 trials, and 
every 4 weeks in 2 trials.
At each of 5 consecutive chemotherapy cycle clinic visits, a tablet computer was brought to 
participants in a private area of clinic waiting rooms to complete the questionnaire. The 
CRPs could provide technical assistance or explain terminology but could not provide 
assistance in symptom rating. At each visit, the CRPs printed reports showing the 
longitudinal trajectory of symptoms and added this information to medical records for 
nurses and oncologists. No specific instructions were given to clinicians regarding how to 
use these reports for clinical trial documentation or patient management. Simultaneously, 
clinicians reported the same symptomatic toxic effects using the standard CTCAE case 
report form utilized in cooperative group trials.
Adherence to self-reporting was systematically tracked, and site staff logged reasons for 
missed patient self-reports. At the third cycle visit (or off-study visit if before the third 
cycle), patients and clinical investigators completed a feedback survey with items regarding 
the ease of use and perceived value of the system.
Statistical Analysis
Participation rate was computed as the number of patients enrolled divided by the number 
approached to participate. Adherence was defined as the number of patients who completed 
the assessment divided by the total number who were alive and enrolled in the trial at each 
given visit. Criteria for determining feasibility were specified a priori as 80% or more 
participation and adherence rates. Descriptive statistics for patient symptom scores and 
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clinician grades included means (SDs) and frequencies of each response category. 
Agreement between patients and clinicians was assessed across all response categories using 
weighted κ statistics, with κ values ranging from 0.01 to 0.20 demarcating slight agreement; 
0.21 to 0.40, fair agreement; 0.41 to 0.60, moderate agreement; and 0.61 or higher, 
substantial agreement.36 Time to grade 2 or higher AEs was analyzed using the Kaplan-
Meier37 approach and is presented as a cumulative incidence curve separately based on 
patient and clinician reports. Feedback surveys were analyzed using descriptive statistics. 
Sample size was capped at 300 based on available funding and an assumption that this 
number would provide robust estimates of feasibility and preliminary estimates of agreement 
for patients who are representative of enrollees in National Clinical Trials Network trials. 
Data collection and statistical analyses were conducted by the Alliance Statistics and Data 
Center (SDC). Data quality was ensured by review of data by the Alliance SDC (A.C.D., D. 
Seisler, and P.J.A.) and by the study chairperson (E.B.) following Alliance SDC policies. 
Statistical analysis was conducted from August 9, 2013, to March 21, 2014, and was 
performed using SAS, version 9.3 (SAS Institute).
Results
This study enrolled patients between March 15, 2007, and August 11, 2011. Thirty-seven 
US sites completed CRP training and actively enrolled patients; 32 (86.5%) sites required 
tablet computers and 5 (13.5%) required wireless connectivity hardware to be set up in 
waiting rooms. A total of 361 patients were approached, with 313 agreeing to participate 
(86.7% participation rate), and 285 (91.1%) were alive and still receiving protocol-directed 
treatment at the time of study initiation. Among the 48 patients who refused participation, 
the most common reasons for nonparticipation were that the patient was not interested (29 
[60.4%]) and was too anxious (6 [12.5%]); only 2 [4.2%] were too sick, 1 [2.1%] did not 
want to use a computer, 1 [2.1%] was too busy, 1 [2.1%] did not like research, and 8 [16.7%] 
did not specify a reason. More participants were women (202 [74.3%]) due to the included 
breast trials (4 of 9 included treatment trials), and most were white (241 [85.5%]); 
denominators differed for some variables because of missing data (Table 1). Within each 
trial, the patients enrolled in this PRO feasibility study were demographically similar to all 
other enrolled patients with respect to age, sex, and race. In some trials, the proportion of 
Hispanic/Latino patients was higher in the overall trial compared with those enrolled in this 
feasibility study because the PRO questionnaire was offered only in English.
During the study, there were 1280 scheduled visits at which participants were expected to 
complete a questionnaire (ie, visits at which patients were alive and enrolled in the 
associated trial). Of these, questionnaires were completed at 1202 visits (93.9% overall 
adherence rate). Adherence was best at baseline and successively declined over time (Figure 
1). Rates exceeded the a priori feasibility threshold of 80% or higher adherence. 
Documented reasons for non adherence included institutional errors (eg, staff forgetting to 
bring tablets to patients at visits) in 27 of 48 (56.3%) cases, internet connectivity problems 
in 5 cases (10.4%), patients feeling too ill in 8 cases (16.7%), and patient refusal in 8 cases 
(16.7%).
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Among the 285 participants, 222 (77.9%) had no missing assessments during the study and 
63 (22.1%) had at least 1 missing assessment during the study. In comparing the linked 
treatment trial, age, sex, race, and ethnicity between the 63 patients with at least 1 missing 
assessment and the 222 patients without missing assessments, none reached statistical 
significance. Women were more likely to have no missing assessments, although this finding 
was not significant (81.0% vs 70.3% for men; P = .07).
Agreement in grade level between patient and clinician reports on toxic effects is reported in 
Table 2. Agreement based on weighted κ statistics was generally fair, with 6 of 13 
symptomatic toxic AEs having weighted κ statistics between 0.21 and 0.40. Agreement was 
highest for vomiting (κ = 0.82) and lowest for hand-foot reaction or rash (κ = 0.03). 
Cumulative incidence of patient and clinician symptomatic toxic AEs of grade 2 or higher, 
shown in Figure 2 and the eFigure in the Supplement, demonstrate lower levels of reporting 
by clinicians compared with patients over time across all toxic AEs except hand-foot 
reaction or rash, where AE rates were low overall. The greatest levels of clinician 
underreporting compared with patients occurred for anorexia, fatigue, nausea, and pain.
Despite these discrepancies between patients and clinicians, most investigators reported in 
the feedback survey that they viewed and discussed patient self-reports at clinic visits and 
found the reports to be useful and accurate (Table 3). The survey was completed by 144 
investigators at all 36 participating sites. The patient feedback survey, returned by 252 of 
285 (88.4%) participants, found that most patients completed the reports themselves, viewed 
the system as easy to use and useful, and believed that the PRO approach improved 
discussions with clinicians (Table 3).
Discussion
To our knowledge, this is the first prospective study assessing patient self-reporting of 
symptomatic AEs in cancer multicenter clinical trials. Most patients were willing and able to 
self-report AEs at consecutive visits and found this process to be easy and useful. Similarly, 
most investigators found the patient reports to be useful and accurate, confirming a prior 
national survey in which more than 90% of investigators projected that patient reporting of 
AEs could improve meaningfulness and accuracy of AEs in clinical research.8
The most common reason for nonadherence was related to staff members; specifically, staff 
members forgot to bring tablets to patients in 56.3% of the documented cases. An additional 
10.4% of missing self-reports were due to internet connectivity problems. These findings 
suggest that adherence rates could be boosted through standardized mechanisms to support 
staff and technology.
In subsequent National Clinical Trials Network studies integrating patient-reported AEs as a 
standard metric, centralized monitoring of adherence and automated reminders have been 
used to prompt staff to remember to collect data.38–41 In addition, approaches have been 
used for between-visit reporting by patients via the internet or automated telephone systems 
to avoid reliance on site staff to bring computers to patients.38,40 Strategies to optimize 
patient response rates will invariably improve as this approach to data collection becomes 
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more commonly used in trials. Nonetheless, the high participation and adherence rates 
observed within the present study suggest immediate feasibility of implementation.
In terms of internet connectivity problems and other technology limitations, there have been 
substantial technical and connectivity advances since this study opened; during the course of 
this study, we observed the frequency of such problems to fall substantially. Virtually all US 
oncology clinics now have high-speed internet in waiting areas, and most patients own a 
wireless device. We anticipate that the connectivity problems experienced in this study will 
be less of a barrier in the future, which is being assessed in follow-up work.38,40
Although most investigators reported viewing PROs at visits and believed that these were an 
accurate reflection of true patient status, there were discrepancies between patient and 
investigator grades, with investigators consistently reporting lower grades than patients. This 
paradoxical finding suggests either that investigators viewed PROs after documenting AEs 
or that investigators did not use the PROs to inform their AE documentation even though 
they found them valuable. In previous studies in which patients and clinicians reported side-
by-side without viewing each other’s documentation, there were similar discrepancies in 
grades4,5,7; in a more recent single-center phase 2 trial, there was more than 90% agreement 
between patients and investigators when investigators were compelled by a computer 
interface to review PROs before documenting AEs.42 Ongoing National Clinical Trials 
Network trials are assessing the sharing of PRO AEs with investigators to assess whether 
investigator grades will better align with PROs.38,40 Nonetheless, unfiltered patient reports 
provide a direct reflection of the patient’s experience with symptomatic AEs, and the US 
Food and Drug Administration has advocated for this approach.43
Adverse events reported by patients but missed by clinicians reflect an area of the patient’s 
experience that may warrant particular attention in the future, both to alleviate patient 
discomfort and identify currently undocumented safety signals. Such focus may be 
particularly salient for targeted therapies and immunotherapies that cause long-standing, 
low-grade toxic effects.
Limitations
There are several limitations of this study. Accrual was dependent on the 9 linked treatment 
trials, which increased at variable rates, leading to a relatively prolonged study period. 
Although we included a range of linked treatment trials in this study to allow for broad 
generalization of study results, the findings may not generalize to clinical trials that enroll 
patients with different characteristics (eg, higher rate of males or higher median age). The 
questionnaire was in English only, and future evaluations should include additional 
languages. Patient reporting was conducted only at clinic visits and not between visits when 
patients may experience important AEs. Ongoing trials are assessing between-visit 
reporting. A centralized backup reminder approach was not used, and this may be 1 reason 
that more than half of missing data were attributable to site staff forgetting to approach 
patients for self-reports at visits. A centralized reminder model is being assessed in ongoing 
work. Although the rates of reporting were high overall, they diminished over time. Work is 
in process to assess adherence rates with longer durations of selfreporting; in other settings, 
adherence has been shown to be durable over time.44
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This study did not track time and effort by investigators, staff, or patients for conducting 
work for the PRO system, and this is a focus of ongoing evaluations in the National Clinical 
Trials Network. The recall period for patient questions in this study was “since your last 
chemotherapy,” which ranged from 1 to 4 weeks in the 9 trials. Ongoing work assessing the 
PRO-CTCAE has used standardized recall periods in clinical trials, and there is evidence 
that recall periods up to 4 weeks correlate with daily reporting, although shorter recall 
periods may be more precise.45,46
The questionnaire and software used in this study were precursors to the NCI’s PRO-
CTCAE item library and software platform, which is now available and should be 
considered the standard approach for assessment of patient-reported AEs in oncology.34,35 
The conceptual framework for the study reported herein as well as the study team’s 
experiences through-out the conduct of this study informed the development of the PRO- 
CTCAE, but the data were not formally available until this analysis. The patient questions 
included in this study mirror the structure of CTCAE items with lay terminology, whereas 
the development of PRO-CTCAE items was based on established methods for designing 
PRO measures.
Performance status data were not universally collected in the linked clinical trials and 
therefore were not available as a baseline variable. It is possible that adherence rates would 
be lower in a population with worse or declining performance status, although adherence 
rates remained high over time in this study and are comparable to those of single-center PRO 
studies that included patients with substantial performance status limitations at 
baseline.22,42,44 Most participants (74.3%) were women due to the composition of linked 
clinical trials and so may not be representative of trials with a different distribution by sex, 
although no significant differences in adherence rates were discernable between men and 
women in this study.
Conclusions
This study demonstrates the feasibility of patient self-reporting of AEs in multicenter cancer 
clinical trials, elucidates areas for further refinement, and paves the way for a more patient-
centered and accurate approach to symptomatic AE reporting in cancer clinical research.
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Is it feasible to collect patient-reported symptomatic adverse events in large multicenter 
oncology clinical trials?
Findings
Among 285 patients enrolled in 9 US multicenter cancer treatment trials, symptomatic 
adverse events were successfully self-reported by paients at 93.9% of expected times. 
Most patients believed that the system was easy to use and useful, and investigators 
thought that the patient-reported adverse event data were useful and accurate.
Meaning
Participants in multicenter cancer trials can report their own symptomatic adverse events, 
which may improve the efficiency and accuracy of safety monitoring in clinical research.
Basch et al. Page 14













Figure 1. Proportion of Clinical Trial Participants Adhering to Symptomatic Adverse Event 
Reporting at Successive Clinic Visits
At each predetermined scheduled clinic visit, the proportion of remaining participants who 
successfully self-reported their own adverse events electronically was tabulated.
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Figure 2. Cumulative Incidence of Common Terminology Criteria for Adverse Events (CTCAE) 
Grade 2 or Higher Patient- and Clinician-Reported Adverse Events
Incidence aggregated from 9 US multicenter clinical trials for constipation (A), fatigue (B), 
hand or foot rash (C), and nausea (D). The eFigure in the Supplement provides the incidence 
for all 13 adverse events. PRO indicates patient-reported outcome.
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Table 1
Characteristics of the 285 Participants
Characteristic No. (%)
Age, median (range), y   57 (24–88)
Sex
 Female 202 (74.3)
 Missing/NRa   13
Raceb
 White 241 (85.5)
 Black   31 (11.0)
 Asian     8(2.8)
 American Indian/Alaska native     2 (0.7)
 Missing/NRa     3
Ethnicity
 Hispanic/Latino     7(2.9)
 Missing/NRa   47
Cancer treatment trial type
 Breast cancer 151 (53.0)
 Colorectal cancer   16 (5.6)
 Lung cancer   10 (3.5)
 Prostate cancer   14 (4.9)
 Supportive care   94 (33.0)
Computer at home
 Yes 222 (82.5)
 Missing/NRa   16
Frequency of internet use
 Regularly 176 (64.7)
 Occasionally/rarely   57 (21.0)
 Never   39 (14.3)
 Missing/NRa   13
Highest educational level
 High school or less   73 (26.8)
 Some college/college degree 152 (55.9)
 Graduate degree   47 (17.3)
 Missing/NRa   13
Abbreviation: NR, not reported.
a
Data were not reported for clinical trials in which these individuals were enrolled. Missing data were removed from the denominator for 
proportions in each demographic category.
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b
Based on self-report. Percentages sum to greater than 100% owing to rounding.
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Table 2
Levels of Agreement Between Symptomatic Toxic Effect Grades as Reported by Patients vs Clinicians
Symptomatic Toxic Effect Weighted κ (95% CI)a
Anorexia 0.22 (0.07 to 0.37)
Constipation 0.39 (0.24 to 0.54)
Cough 0.36 (0.16 to 0.56)
Diarrhea 0.63 (0.49 to 0.76)
Dyspnea 0.32 (0.13 to 0.50)
Fatigue 0.33 (0.17 to 0.49)
Hand or foot rash 0.03 (−0.05 to 0.11)
Mouth sores 0.44 (0.25 to 0.63)
Nausea 0.65 (0.49 to 0.81)
Neuropathy 0.48 (0.33 to 0.64)
Pain 0.61 (0.48 to 0.74)
Vomiting 0.82 (0.62 to 1.00)
Watery eyes 0.23 (0.00 to 0.45)
a
Weighted κ values ranging from 0.01 to 0.20 demarcate slight agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60, moderate agreement; and 0.61 
or higher, substantial agreement.
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Table 3
Clinical Investigator and Patient Feedback Surveys
Survey Item Respondents, No. (%)
Clinical Investigator Feedbacka
Patient-reported symptomatic toxicities
 Were reviewed at visits 131/143 (91.6)
 Were discussed with patients at visits 110/144 (76.4)
 Are useful for monitoring toxicities 133/141 (94.3)
 Could be a source of research-grade data 120/143 (83.9)
 Were an accurate reflection of patient clinical status 119/143 (83.2)
Impression of relationship between adverse event grade severities reported by patients vs clinicians
 They are generally the same   63/143 (44.1)
 Patients generally grade more severe than clinicians   50/143 (35.0)
 Patients generally grade less severe than clinicians   13/143 (9.1)
 Don’t know   17/143 (11.9)
Patient Feedbackb
Person who entered symptom grades
 Myself 220/250 (88.0)
 Relative or friend     5/250 (2.0)
 Professional caregiver   16/250 (6.4)
 Other     9/250 (3.6)
The patient adverse event reporting system
 Was easy to use 234/251 (93.2)
 Was useful 230/247 (93.1)
 Improved discussions with mydoctor/nurse 211/247 (85.4)
a
Overall, there were 144 clinical investigator respondents across 37 sites, but not all investigators responded to all questions; therefore, the 
denominator for each question varies with missing responses subtracted.
b
Overall, there were 252 patient respondents of 285 study participants, but not all patients responded to all questions; therefore, the denominator 
for each question varies with missing responses subtracted.
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